Preventing GVHD after donor lymphocyte infusion for relapsed blood cancer
Part of Immune system & allergy clinical trials.
This trial looks at using low doses of cyclophosphamide or CNI (a type of immune-suppressing drug) to prevent graft-versus-host disease (GVHD) in people who get a donor lymphocyte infusion after their blood cancer returns. It may help control GVHD while still fighting the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer (like leukemia or lymphoma) that came back after a stem cell transplant.
- You are scheduled to receive a donor lymphocyte infusion (DLI) to treat the relapse.
- Your donor was not a fully matched sibling – it could be a partially matched family member or an unrelated donor.
- You are generally well enough to be up and about (ECOG score 0-2).
- You do not have serious heart problems, active infections, or other cancers needing treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of donor immune cell infusion (called DLI) that has been processed to remove certain cells that might limit its effectiveness. It is for people whose blood cancer has come back after a stem cell transplant and who have not responded well to standard donor cell treatments.
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This trial tests a new way to prevent graft-versus-host disease (GVHD) after a stem cell transplant in people who have already received PD-1 immunotherapy. The goal is to make the transplant safer and more effective.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Hear when a new Acute Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.